Recombinant Human CHRM1 protein

中文名： 毒蕈碱型胆碱受体M1(CHRM1)重组蛋白
别名： CHRM1；Muscarinic acetylcholine receptor M1

货号: PA1000-8205

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	CHRM1
Uniprot No	P11229
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	210-366aa
氨基酸序列	RIYRETENRARELAALQGSETPGKGGGSSSSSERSQPGAEGSPETPPGRCCRCCRAPRLLQAYSWKEEEEEDEGSMESLTSSEGEEPGSEVVIKMPMVDPEAQAPTKQPPRSSPNTVKRPTKKGRDRAGKGQKPRGKEQLAKRKTFSLVKEKKAART
预测分子量	20.8 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于CHRM1重组蛋白的3篇参考文献示例(注：内容为概括性示例，具体文献请通过学术数据库核实)：

1. **文献名称**：*"Expression and functional characterization of human M1 muscarinic acetylcholine receptor in HEK293 cells"*

**作者**：Jones, A. et al.

**摘要**：该研究成功在HEK293细胞中重组表达了人源CHRM1蛋白，并通过放射性配体结合实验验证其与乙酰胆碱的高亲和力，证实重组受体具备天然受体的药理学特性。

2. **文献名称**：*"Structural insights into the activation mechanism of CHRM1 using cryo-EM"*

**作者**：Zhang, L. et al.

**摘要**：利用冷冻电镜技术解析了CHRM1重组蛋白与激动剂结合的三维结构，揭示了其激活过程中跨膜结构域的构象变化，为靶向药物设计提供结构基础。

3. **文献名称**：*"CHRM1-mediated signaling pathways in Alzheimer's disease models"*

**作者**：Smith, R. et al.

**摘要**：通过重组CHRM1蛋白研究其与β-淀粉样蛋白的相互作用，发现CHRM1信号异常可能加剧阿尔茨海默病模型中的突触功能障碍，提示其作为治疗靶点的潜力。

**建议**：如需具体文献，可通过PubMed或Google Scholar检索关键词“CHRM1 recombinant protein”“M1 muscarinic receptor expression”等获取最新研究。

背景信息

**Background of CHRM1 Recombinant Protein**

The **CHRM1 (Cholinergic Receptor Muscarinic 1)** protein is a G protein-coupled receptor (GPCR) that binds acetylcholine, a key neurotransmitter in the central and peripheral nervous systems. It is one of five muscarinic receptor subtypes (M1-M5) and is primarily expressed in the brain, particularly in regions associated with cognition, memory, and learning, such as the hippocampus and cortex. CHRM1 activates signaling pathways via coupling to Gq/11 proteins, triggering downstream effectors like phospholipase C (PLC), which leads to the production of secondary messengers (e.g., IP3 and DAG) and modulates neuronal excitability, synaptic plasticity, and neurotransmitter release.

Dysregulation of CHRM1 is linked to neurological disorders, including Alzheimer’s disease, schizophrenia, and Parkinson’s disease, making it a therapeutic target for drugs aiming to enhance cholinergic signaling. Recombinant CHRM1 protein, produced through heterologous expression systems (e.g., HEK293 or insect cells), retains native structural and functional properties. Its production often involves tagging (e.g., His or FLAG tags) for purification and detection.

Recombinant CHRM1 is crucial for *in vitro* studies, enabling ligand-binding assays, receptor activation profiling, and structural analyses (e.g., cryo-EM). It also aids in drug discovery for selective agonists/antagonists and understanding receptor interactions with signaling partners. By providing a controlled, high-purity protein source, recombinant CHRM1 accelerates research into cholinergic pathways and the development of targeted neurotherapeutics.